Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration
Jonathan H Lim, Sanjeewa S Wickremasinghe, Jing Xie, Devinder S Chauhan, Paul N Baird, Luba D Robman, Gregory Hageman, Robyn H Guymer
American Journal of Ophthalmology | ELSEVIER SCIENCE INC | Published : 2012
Awarded by NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL (NHMRC, CANBERRA, Australia)
Awarded by National Institute of Health (NIH, Bethesda, Maryland)
PUBLICATION OF THIS ARTICLE WAS FUNDED BY NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL (NHMRC, CANBERRA, Australia) project grant 590205 and National Institute of Health (NIH, Bethesda, Maryland) R24 EY (G.H., R.G., P.B.). The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian government. Dr Wickremasinghe was supported by a Novartis fellowship during the 2008/2009 period. Involved in design and conduct of the study (G.H., R.G.); collection (J.L., S.W., D.C.), management (S.W., J.L.), analysis (J.X, L.R.), and interpretation of the data (R.G., G.H., P.B.); and preparation (S.W., J.L.), review, or approval of the manuscript (R.G., P.B., OH.). This study was approved by the Human Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital (RVEEH) prior to study commencement. Research adhered to the tenets of the Declaration of Helsinki and participants provided written, informed consent prior to participation.